Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Nektar Therapeutics - Key Facts

Nektar Therapeutics - Key Employees

Nektar Therapeutics - Key Employee Biographies

Nektar Therapeutics - Major Products and Services

Nektar Therapeutics - History

Nektar Therapeutics - Company Statement

Nektar Therapeutics - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Nektar Therapeutics - Business Description

Geographical Segment: Europe

Performance

Geographical Segment: United States

Performance

Nektar Therapeutics - Corporate Strategy

Nektar Therapeutics - SWOT Analysis

SWOT Analysis - Overview

Nektar Therapeutics - Strengths

Nektar Therapeutics - Weaknesses

Nektar Therapeutics - Opportunities

Nektar Therapeutics - Threats

Nektar Therapeutics - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Nektar Therapeutics, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 08, 2019: Nektar Therapeutics reports financial results for the first quarter of 2019

Feb 28, 2019: Nektar Therapeutics reports fourth quarter and year-end 2018 financial results

Nov 14, 2018: Nektar appoints Wei Lin, M.D., as Senior Vice President of clinical development and Head of Nektar's oncology programs

Nov 07, 2018: Nektar Therapeutics reports financial results for the third quarter of 2018

Sep 01, 2018: Nektar Therapeutics strengthens Board of Directors with appointment of Veteran Biotechnology Executive Karin Eastham

Aug 08, 2018: Nektar Therapeutics reports financial results for the second quarter of 2018

May 10, 2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018

Mar 01, 2018: Nektar Therapeutics Announces Fourth Quarter And Year-End 2017 Financial Results

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide array of functional attributes, which optimizes and enhances the profile of wide range of molecules including many classes of drugs targeting numerous disease areas. The company’s products focus on various therapeutic areas, including, cancer, pain, infections and immunology among others. Its research and development activities involve peptides, proteins, antibodies, small molecule drugs and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics Key Recent Developments

May 08,2019: Nektar Therapeutics reports financial results for the first quarter of 2019
Feb 28,2019: Nektar Therapeutics reports fourth quarter and year-end 2018 financial results
Nov 14,2018: Nektar appoints Wei Lin, M.D., as Senior Vice President of clinical development and Head of Nektar's oncology programs
Nov 07,2018: Nektar Therapeutics reports financial results for the third quarter of 2018
Sep 01,2018: Nektar Therapeutics strengthens Board of Directors with appointment of Veteran Biotechnology Executive Karin Eastham

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company